Funding Rounds
Prokarium

Prokarium Series B (2023, $30M)

Prokarium

Immunotherapy for bladder cancer.

View Company Profile

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Stage: Series B

Raised Amount: $30.00M

Raised Date: 2023-09-01